Lurasidone in first-episode psychosis with predominant depressive symptoms: a case report

被引：4
|
作者：
Ricci, Valerio [1 ,3 ]
Di Salvo, Gabriele [2 ]
Maina, Giuseppe [2 ]
机构：
[1] San Luigi Gonzaga Univ Hosp, Dept Psychiat, Orbassano, Regione Gonzole, Italy
[2] Univ Turin, Rita Levi Montalcini Dept Neurosci, Turin, Italy
[3] San Luigi Gonzaga Univ Hosp, Dept Psychiat, Reg Gonzole 10, I-10043 Turin, Italy
来源：
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY | 2023年 / 38卷 / 04期
关键词：
depression; first-episode psychosis; lurasidone; negative symptoms; psychotic symptoms; schizophrenia; SCHIZOPHRENIA; 5-HT7;
D O I：
10.1097/YIC.0000000000000465
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Lurasidone is an atypical antipsychotic approved for the treatment of schizophrenia and bipolar depression. It seems to have an antidepressant effect due to 5-HT7 as well as 5-HT2A and 5-HT1a receptor affinity. Here we present a case of a 19-year-old male patient with first-episode psychosis (FEP) and predominant depressive symptoms. Remarkable clinical and functional improvement was observed 3 months after the beginning of lurasidone treatment. The patient's depressive symptoms disappear with a dramatic reduction of psychotic ones, with good tolerance of the drug and without adverse effects. Lurasidone seems to be a promising treatment option for FEP with predominant depressive symptoms.
引用
收藏
页码：275 / 280
页数：6
相关论文
共 50 条
  • [1] Premorbid negative symptoms in first-episode psychosis
    Cuesta, Manuel J.
    Peralta, Victor
    Gil, Patxi
    Artamendi, Maria
    EUROPEAN JOURNAL OF PSYCHIATRY, 2007, 21 (03): : 220 - 229
  • [2] Depression and Depressive Symptoms in First Episode Psychosis
    Romm, Kristin Lie
    Rossberg, Jan Ivar
    Berg, Akiah Ottesen
    Barrett, Elizabeth Ann
    Faerden, Ann
    Agartz, Ingrid
    Andreassen, Ole A.
    Melle, Ingrid
    JOURNAL OF NERVOUS AND MENTAL DISEASE, 2010, 198 (01) : 67 - 71
  • [3] Anxiety symptoms in first-episode psychosis
    Karpov, Boris
    Kieseppa, Tuula
    Lindgren, Maija
    Wegelius, Asko
    Suvisaari, Jaana
    EARLY INTERVENTION IN PSYCHIATRY, 2021, 15 (03) : 569 - 576
  • [4] Cariprazine as a treatment for negative psychotic symptoms in first-episode psychosis: case series
    Demjaha, Arsime
    Iacoponi, Eduardo
    Hansen, Lars
    Peddu, Pradeep
    McGuire, Philip
    BJPSYCH OPEN, 2022, 8 (03):
  • [5] Duration of active psychosis and first-episode psychosis negative symptoms
    Lyne, John
    Joober, Ridha
    Schmitz, Norbert
    Lepage, Martin
    Malla, Ashok
    EARLY INTERVENTION IN PSYCHIATRY, 2017, 11 (01) : 63 - 71
  • [6] Premorbid adjustment and remission of positive symptoms in first-episode psychosis
    Amminger, GP
    Resch, F
    Mutschlechner, R
    Friedrich, MH
    Ernst, E
    EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 1997, 6 (04) : 212 - 218
  • [7] Depressive symptoms and suicidal behavior after first-episode psychosis: A comprehensive systematic review
    Coentre, Ricardo
    Talina, Miguel Cotrim
    Gois, Carlos
    Figueira, Maria Luisa
    PSYCHIATRY RESEARCH, 2017, 253 : 240 - 248
  • [8] Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel
    Bernardo, Miquel
    Marsa, Marina Diaz
    Gonzalez-Pinto, Ana
    Carrasco, Manuel Martin
    Sola, Victor Perez
    Saiz, Pilar Alejandra
    Vieta, Eduard
    Torrens, Marta
    Arango, Celso
    Crespo-Facorro, Benedicto
    NEUROLOGY AND THERAPY, 2025, 14 (01) : 85 - 98
  • [9] Assessment of Posttraumatic Symptoms in Patients With First-Episode Psychosis
    Schaefer, Ingo
    Morgan, Craig
    Demjaha, Arsime
    Morgan, Kevin
    Dazzan, Paola
    Fearon, Paul
    Jones, Peter B.
    Doody, Gillian A.
    Leff, Julian
    Murray, Robin M.
    Fisher, Helen L.
    JOURNAL OF NERVOUS AND MENTAL DISEASE, 2011, 199 (11) : 896 - 898
  • [10] PERSONALITY DOMAINS AND NEGATIVE SYMPTOMS IN FIRST-EPISODE PSYCHOSIS
    Serretti, Alessandro
    Rodriguez-Jimenez, Roberto
    Romero-Ferreiro, Veronica
    Nunez-Doyle, Aggie
    Fabbri, Chiara
    Fanelli, Giuseppe
    Scala, Mauro
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2025, 28 : i229 - i229
12345